DEEP Overview

Small-Cap Stocks Gaining Attention: U.S. small-cap stocks are experiencing renewed interest due to favorable tax policies, strong valuations, and bullish technical signals, with ETFs like the iShares Russell 2000 ETF and others showing modest performance gains recently.

Potential for Growth: Despite still lagging behind larger stocks year-to-date, small caps may be poised for a comeback as earnings momentum and favorable market conditions align, presenting an opportunity for investors to capitalize on this underappreciated asset class.

Small-Cap Stocks Performance: Small-cap U.S. stocks, represented by the Russell 2000 index, are showing signs of recovery with an 18.58% increase over three months, nearly matching the S&P 500's performance, although they still lag behind large-cap stocks for the year.

Earnings Growth Comparison: In Q2, small-cap companies reported a 16.9% increase in earnings and 7.8% higher revenues, with a significant proportion beating estimates, indicating potential growth despite ongoing challenges compared to large-cap firms.

Kosmos Energy's Gas Production Start: Kosmos Energy Ltd. announced the commencement of gas production at the Greater Tortue Ahmeyim LNG project, with Phase 1 expected to produce 2.3 million tonnes of LNG annually, marking a significant milestone for the partnership and West Africa's LNG ambitions.

Financial Outlook and Stock Performance: Following the announcement, KOS shares rose by 3.22% in premarket trading, while the company aims to enhance financial resilience through disciplined capital allocation and reducing leverage as it ramps up production towards its target of ~90,000 boepd.

Mpox Outbreak and Global Response: Authorities in Europe and China are increasing screening for a new strain of mpox, known as clade I, which has been confirmed in Sweden and is spreading in Africa. The World Health Organization has declared it a global health emergency, with over 16,000 cases reported in Africa this year.

Vaccination Efforts and Treatment Challenges: Two vaccines have received emergency authorizations, with efforts to expand their use among at-risk populations. However, a study indicated that the antiviral drug tecovirimat did not reduce the duration of mpox lesions in affected individuals.